Navigation Links
Aerovance Secures $38 Million in Equity Financing

BERKELEY, Calif., April 7 /PRNewswire/ -- Aerovance Inc. today announced that it has secured $38 million in additional equity financing. In previous transactions since formation in 2004, the company has raised $92 million in equity financing and $10 million in debt financing.

This financing round, which consists of two tranches, was led by new investor ProQuest Investments and includes the full pro rata participation of existing investors Apax Partners, Clarus Ventures, Alta Partners, Lehman Brothers, NGN Capital and Burrill & Co., as well as that of new investor BB Biotech Ventures. Aerovance closed on $20 million and has the right to call the remaining $18 million after six months.

The financing will support the company's recently initiated Phase IIb clinical trial of inhaled Aerovant(TM) in patients with uncontrolled asthma and Phase III enabling activities for this program. These activities will include scale-up of the dry powder spray-drying process and preparation for a long-term toxicology study.

In connection with the financing, Alain Schreiber, M.D., a partner with ProQuest Investments, will join Aerovance's board of directors. Ann Hanham, Ph.D., a managing director with Burrill & Company-and an original investor in Aerovance, will also join the company's board of directors. Hingge Hsu, M.D., a former partner with Lehman Brothers, will step down from his role as a board member.

"Our investment in Aerovance is in line with ProQuest's strategy of targeting companies with breakthrough technology and products, proven management, large market potential and achievable business strategies," said Dr. Schreiber.

Mark Perry, Aerovance's president and CEO, said: "This significant capital raise at a time of great challenge and uncertainty in the financial markets is an important indication of investor enthusiasm for our lead candidate, Aerovant. We are pleased to advance Aerovant into the Phase IIb study, AeroTrial(TM), to evaluate the compound's safety and efficacy in patients living with uncontrolled asthma."

We welcome both Alain Schreiber and Ann Hanham to our board of directors. They have extensive drug development and commercialization expertise that complement the experience of our existing board members and senior management team. On behalf of our board, I would like to thank Hingge Hsu for his numerous contributions and valuable guidance since Aerovance's formation."

Aerovant is a recombinant human IL-4 variant that is a potent inhibitor of both the IL-4 and IL-13 receptors. Aerovance acquired the worldwide rights to the drug candidate when the company was formed as a spin-out of Bayer Pharmaceuticals Corporation in 2004. Aerovant is currently in a Phase IIb clinical trial for the treatment of uncontrolled asthma.

AeroTrial is a late-stage clinical study using a dry powder formulation and follows positive clinical data from two Phase IIa studies in which Aerovant demonstrated significant benefit in asthmatics who were experimentally challenged with inhaled allergen (The Lancet 2007, 370: 1422-31). The dry powder formulation that will be used in AeroTrial was well tolerated in a recently completed Phase I study in asthmatics. By using a medication based on a protein occurring naturally in the body, AeroTrial seeks a non-steroidal solution to getting control of asthma. For more information, visit

Aerovance Inc. is a Berkeley, Calif.-based biopharmaceutical company focused on the development and commercialization of breakthrough therapies for the treatment of respiratory and inflammatory diseases. For more information, visit

    Contact: Andreas Marathovouniotis or David Schull
    Russo Partners
    212-845-4235 or 212-845-4271

    Dave Happel
    Aerovance Inc.

SOURCE Aerovance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Aerovance Appoints Babatunde A. Otulana, M.D., as Chief Medical Officer
2. Aerovance Secures $20 Million in Debt Financing
3. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
4. Pearl Therapeutics Secures $8 Million in Debt Financing
5. Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
6. Sopherion Therapeutics Secures $55 Million in Series C Funding
7. Northwest Biotherapeutics Secures $700,000 Equity Financing
8. Intelligroup Secures Multi-Million Dollar COSMOS Implementation with Almac Clinical Services
9. TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing
10. Pharmacyclics Secures $5.0 Million in Debt Financing
11. EcoSphere(R) Biolatex(TM) Secures Funding from Granholm and Invest Michigan!
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... of the year and one of the premier annual events for pharmaceutical manufacturing: ... from 8–11 November 2015, where ISPE hosted the largest number of attendees in ...
Breaking Biology Technology:
(Date:11/19/2015)... 19, 2015  Based on its in-depth analysis of ... BIO-key with the 2015 Global Frost & Sullivan Award ... Sullivan presents this award to the company that has ... needs of the market it serves. The award recognizes ... expands on customer base demands, the overall impact it ...
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has ... of MIT and Harvard for use of its ... information management tools. The partnership will support the ... biological and chemical research information internally and with ... be used for managing the Institute,s electronic laboratory ...
Breaking Biology News(10 mins):